Patent · US Active

Integrin antagonists

US10703752B2 · kind B2 · utility

0Cited by
1References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 19, 2019
Grant dateJul 7, 2020
Priority date
Expiry dateAug 19, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to novel integrin antagonists of Formula I and their use as a medicament, in particular for inhibiting neovascularization.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.